J&J;, Alkermes Drug Rejected by FDA
- Share via
Johnson & Johnson and partner Alkermes Inc. said U.S. regulators rejected their twice-a-month form of the Risperdal schizophrenia drug, sending Alkermes shares down 68%.
Investors are concerned about more bad news from the Food and Drug Administration after a string of rejections or delays for medications. The FDA raised questions about research for Risperdal, Johnson & Johnson said.
Shares of Alkermes fell $10.86 to $5.15 on Nasdaq. New Brunswick, N.J.-based Johnson & Johnson shares fell $1.76 to $50.50 on the New York Stock Exchange.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
